###### Strengths and limitations of this study

-   A prognostic marker for each driver mutation in non-small cell lung cancer (NSCLC) has not yet been determined.

-   MUC5B is a favourable postoperative prognostic marker for epidermal growth factor receptor (*EGFR*) mutant NSCLC.

-   MUC5AC is not correlated with postoperative prognosis regardless of *EGFR* mutation status.

-   The function of MUC5B in *EGFR* mutant NSCLC remains unknown.

Introduction {#s1}
============

Lung cancer is the primary cause of cancer-related death in the USA and worldwide.[@R1] Non-small cell lung cancer (NSCLC) accounts for approximately 80--85% of all lung cancers.[@R1] Currently, targeted therapies for non-resectable NSCLC have progressed rapidly, based on the discovery of pharmacologically treatable driver mutations in epidermal growth factor receptor (*EGFR*) and fusions of anaplastic lymphoma kinase (ALK).[@R2] [@R3] These moleculary targeted therapies have revealed distinct and/or overlapping tumorigenic pathways associated with each driver mutation, especially regarding the mechanisms of tumour recurrence.[@R4] Genetic screening of driver mutations, including *EGFR* mutations and *ALK* fusions, is now common for metastatic NSCLC but not for surgically resected primary NSCLC.[@R5] In the ALCHEMIST lung cancer trials (<http://www.cancer.gov/researchandfunding/areas/clinical-trials/nctn/alchemist>), patients whose primary lung tumours carry *EGFR* mutations (*EGFR*-mutant patients) are being tested for adjuvant therapy of erlotinib targeting EGFR mutations. However, a favourable or poor prognostic biomarker associated with *EGFR* mutations is not known. Such biomarkers will be useful to determine *EGFR*-mutant patients who would benefit most from the adjuvant therapy of erlotinib and to avoid such unnecessary therapy after surgery in patients who would not benefit.

Recently, we reported that decreased expression of *Nkx2--1* (also known as TTF-1) in a mouse model of *EGFR* mutant NSCLC reduced the number and size of lung tumours,[@R6] and extended the survival of the mice (see online [supplementary figure](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2015-008366/-/DC1) S1). Unexpectedly, the decreased *Nkx2--1* induced the expression of a mucin protein MUC5B but not MUC5AC in *EGFR*-mutant lung tumours in the mice,[@R6] suggesting that MUC5B may serve as a favourable prognostic marker associated with *EGFR* mutant NSCLC in humans. In the present study, we assessed whether the expression of MUC5B in the primarily resected *EGFR* mutant or wild-type lung tumours is linked to survival of the patients after surgery. Our study provides a novel approach to assess prognosis for patients whose primarily resected lung tumours carry *EGFR* mutations.

Methods {#s2}
=======

Study population {#s2a}
----------------

Among the patients who underwent surgical resection at Nagasaki University Hospital and related facilities between June 1996 and March 2013, patients who were tested for the presence or absence of *EGFR* mutations were selected for this study. The *EGFR* mutations were confirmed internally or externally (LSI Medience Corporation, Japan). We further selected the patients whose clinicopathological characteristics were retrieved from the patients' charts and whose prognosis was followed at our institution and related facilities. We enrolled 159 patients (*EGFR*-mutant type: n=78, *EGFR* wild type: n=81) for this study ([table 1](#BMJOPEN2015008366TB1){ref-type="table"}). All investigations were approved by our institution and related facilities' review boards, and informed consent was obtained from all participants prior to the study.

###### 

Baseline characteristics of the 159 patients with NSCLC

  Number of patients                 
  ---------------------------------- ---------------
  Median age (range, years)          67.5 (32--90)
  Gender                             
   Male                              103 (65%)
   Female                            56 (35%)
  Smoking status                     
   Non-smoker                        54 (34%)
   Smoker                            105 (66%)
  Histological type                  
   Adenocarcinoma: bronchoalveolar   33 (21%)
   Adenocarcinoma                    91 (57%)
   Squamous cell carcinoma           32 (20%)
   Adenosquamous carcinoma           2 (1%)
   Other\*                           1 (1%)
   Median tumour size (range, mm)    32.4 (8--120)
  Degree of differentiation          
   Well                              55 (35%)
   Moderately                        69 (43%)
   Poorly                            28 (18%)
   MD                                7 (4%)
  Stage                              
   IA/IB                             81 (51%)
   IIA/IIB                           40 (25%)
   IIIA/IIIB                         38 (24%)
  Tumour status                      
   T1--2                             136 (86%)
   T3--4                             23 (14%)
  Nodal status                       
   N0                                103 (65%)
   N1--3                             56 (35%)
  Lymphatic invasion                 
   Negative                          56 (35%)
   Positive                          102 (64%)
   MD                                1 (1%)
  Venous invasion                    
   Negative                          76 (48%)
   Positive                          82 (52%)
   MD                                1 (1%)
  Adjuvant chemotherapy              
   Yes                               85 (53%)
   No                                74 (47%)
  EGFR                               
   Wild type                         81 (51%)
   Mutant type                       78 (49%)

Data are median (range) or number (%) unless otherwise stated.

\*Other mean NSCLC neuroendocrine.

EGFR, epidermal growth factor receptor; MD, missing data; NSCLC, non-small cell lung cancer.

Clinicopathological evaluation {#s2b}
------------------------------

Histological classification of NSCLC was designated as three types---well, moderately and poorly differentiated---based on the predominant features according to the WHO classification.[@R7] The patients remained for a median follow-up period of 1680 days, ranging from 55 to 4503 days. For all patients, periodic inspection with chest X-ray, CT scan and tumour marker assays was performed at least every 6 months to confirm the presence or absence of recurrence, even if patients experienced no problems or no symptoms.

Antibody information {#s2c}
--------------------

For immunohistochemical staining, primary antibodies were used at the following concentrations: rabbit polyclonal anti-MUC5B (1:200; sc-20 119, Santa Cruz Biotechnology) and rabbit polyclonal anti-MUC5AC (1:50; sc-20 118, Santa Cruz Biotechnology).

Sample preparation, selection and immunohistochemistry {#s2d}
------------------------------------------------------

The 5 µm thick formalin-fixed paraffin-embedded (FFPE) lung sections were deparaffinised in dimethylbenzene and dehydrated through a graded alcohol series. For antigen retrieval, the FFPE lung sections were incubated in 10 mM citric acid (pH 6) at 121°C for 15 min and then washed in phosphate-buffered saline (PBS). Next, the lung sections were immersed in 3% H~2~O~2~ solution for 30 min to block the endogenous peroxidase followed by incubation with each primary antibody at 4^o^C overnight. After washing in PBS, the lung sections were incubated with the peroxidase-conjugated secondary antibodies (Simple Stain MAX-PO kit, Nichirei, Tokyo, Japan) for 30 min at room temperature. For immunohistochemistry (IHC) staining, the lung sections were visualised with a diaminobenzidine (DAB: brown) kit (Histofine, Nichirei) and counterstained with H&E. The lung sections visualised with DAB were dehydrated with alcohol and dimethylbenzene and mounted in a conventional fashion.

Normal bronchial tissue specimens that moderately expressed MUC5B were prepared as positive controls in all cases. Normal gastric mucosa tissue specimens that moderately expressed MUC5AC were prepared as positive controls in all cases. Negative controls were also prepared in all cases. MUC5B and MUC5AC staining was evaluated by IHC by two independent trained observers (KW and TT). The pathological criteria were determined by reference to guideline for human epidermal growth factor receptor 2 (Her2/neu) testing in breast cancer (score 0, no staining observed or incomplete faint/barely perceptible cytoplasmic staining of \<10% of tumour cells; score 1, incomplete faint/barely perceptible cytoplasmic staining of \>10% of tumour cells; score 2, incomplete weak/moderate cytoplasmic staining of \>10% of tumour cells; score 3, complete and intense cytoplasmic staining of \>30% of tumour cells).[@R8] Scores 0 and 1 were further categorised as negative, and scores 2 and 3 as positive.

Statistical analysis {#s2e}
--------------------

For univariate analysis, categorical data were analysed by the χ^2^ test, Fisher\'s exact test or the Cochran-Armitage test. Continuous data were expressed as a mean using the Mann-Whitney U test or the Kruskal-Wallis test. The overall survival (OS) and relapse-free survival (RFS) were calculated according to the Kaplan-Meier method, and differences between groups were tested for significance using the log-rank test. Participants who neither died nor had recurrence were censored at the time of their last follow-up. The prognostic relevance of a single factor was determined by multivariate Cox regression analysis. A p value of 0.05 or less was considered significant. SPSS V.17 software (SPSS Japan, Tokyo, Japan) was used for the analysis.

Results {#s3}
=======

Expression of MUC5B and MUC5AC in human NSCLC {#s3a}
---------------------------------------------

Since MUC5B is an abundant cytoplasmic and secreted protein, we assessed whether MUC5B could be used as a prognostic marker for patients with NSCLC carrying *EGFR* mutations in primary resected human lung tumours. Primary resected NSCLC tumours were tested immunohistochemically for the presence of MUC5B. MUC5B staining was detected in the cytoplasm of NSCLC cells in 27 of the 78 samples with *EGFR* mutations and 29 of the 81 samples with wild-type *EGFR* ([figure 1](#BMJOPEN2015008366F1){ref-type="fig"}A, B). The NSCLC samples were also tested using MUC5AC antibody, detecting expression of MUC5AC in the cytoplasm of NSCLC cells in 20 of the 73 samples with *EGFR* mutations and 24 of the 79 samples with wild-type *EGFR* ([figure 1](#BMJOPEN2015008366F1){ref-type="fig"}C, D). These results indicate that both MUC5B and MUC5AC are expressed in a portion of human NSCLC.

![Immunohistochemical staining for MUC5B and MUC5AC expression in NSCLC. Representative images of immune-positive staining for MUC5B in non-small cell lung cancer (A), negative staining (B), positive staining for MUC5AC (C) and negative staining (D).](bmjopen2015008366f01){#BMJOPEN2015008366F1}

Prognostic association of MUC5B or MUC5AC with *EGFR* mutant or wild-type NSCLC {#s3b}
-------------------------------------------------------------------------------

Expression of MUC5B in NSCLC tumours carrying *EGFR* mutations was not correlated with clinicopathological parameters, including age, gender, smoking status, histological type, tumour size, degree of differentiation, stage, tumour status, nodal status, lymphatic invasion, venous invasion or adjuvant chemotherapy ([table 2](#BMJOPEN2015008366TB2){ref-type="table"}). Expression of MUC5B in NSCLC tumours with wild-type *EGFR* was not correlated with all of the clinicopathological parameters but was correlated with the histological type (see online [supplementary table](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2015-008366/-/DC1) S1).

###### 

Association with clinicopathological data and the expression of MUC5B of patients with EGFR-mutant NSCLC

  Parameters                                         MUC5B           p Value         
  ---------------------------------- --------------- --------------- --------------- --------
  Median age (range, years)          66.9 (41--85)   66.7 (42--83)   67.3 (41--85)   0.674
  Gender                                                                             
   Male                              35 (45%)        22 (28%)        13 (17%)        
   Female                            43 (55%)        29 (37%)        14 (18%)        0.6721
  Smoking status                                                                     
   Non-smoker                        42 (54%)        28 (36%)        14 (18%)        
   Smoker                            36 (46%)        23 (29%)        13 (17%)        0.7971
  Histological type                                                                  
   Adenocarcinoma: bronchoalveolar   27 (35%)        16 (21%)        11 (14%)        
   Adenocarcinoma                    43 (55%)        29 (37%)        14 (18%)        
   Squamous cell carcinoma           8 (10%)         6 (8%)          2 (3%)          0.6522
   Median tumour size (range, mm)    25.7 (8--60)    26.1 (8--60)    24.9 (8--50)    0.8771
  Degree of differentiation                                                          
   Well                              35 (45%)        22 (28%)        13 (17%)        
   Moderately                        28 (36%)        19 (24%)        9 (12%)         
   Poorly                            11 (14%)        6 (8%)          5 (6%)          0.7348
   MD                                4 (5%)          4 (5%)          0 (0%)          
  Stage                                                                              
   IA/IB                             46 (59%)        29 (37%)        17 (22%)        
   IIA/IIB                           14 (18%)        8 (10%)         6 (8%)          
   IIIA/IIIB                         18 (23%)        14 (18%)        4 (5%)          0.4162
  Tumour status                                                                      
   T1--2                             68 (87%)        42 (54%)        26 (33%)        
   T3--4                             10 (13%)        9 (12%)         1 (1%)          0.0797
  Nodal status                                                                       
   N0                                53 (68%)        35 (45%)        18 (23%)        
   N1--3                             25 (32%)        16 (21%)        9 (12%)         0.8599
  Lymphatic invasion                                                                 
   Negative                          35 (45%)        26 (33%)        9 (12%)         
   Positive                          42 (54%)        24 (31%)        18 (23%)        0.1165
   MD                                1 (1%)          1 (1%)          0 (0%)          
  Venous invasion                                                                    
   Negative                          45 (58%)        30 (38%)        15 (19%)        
   Positive                          32 (41%)        20 (26%)        12 (15%)        0.7057
   MD                                1 (1%)          1 (1%)          0 (0%)          
  Adjuvant chemotherapy                                                              
   Yes                               33 (42%)        20 (26%)        13 (17%)        
   No                                45 (58%)        31 (40%)        14 (18%)        0.4475

Data are median (range) or number (%) unless otherwise stated.

EGFR, epidermal growth factor receptor; MD, missing data; NSCLC, non-small cell lung cancer.

OS and RFS for patients with NSCLC carrying *EGFR* mutations or wild-type *EGFR* were assessed. In a cohort of patients whose resected NSCLC tumours carried *EGFR* mutations, univariate analysis showed significant differences (p\<0.05) in OS in expression of MUC5B, tumour size, histological type, degree of differentiation, stage, lymphatic invasion and venous invasion, and in RFS in expression of MUC5B, tumour size, degree of differentiation, stage, lymphatic invasion and venous invasion ([table 3](#BMJOPEN2015008366TB3){ref-type="table"}). Patients whose tumours expressed MUC5B (MUC5B-positive patients) survived significantly longer than patients whose tumours did not express MUC5B (MUC5B-negative patients) in both OS (5-year OS; 95.8% vs 65.1%, p=0.0098; [figure 2](#BMJOPEN2015008366F2){ref-type="fig"}A) and RFS (5-year RFS; 69.9% vs 44%, p=0.0187; [figure 2](#BMJOPEN2015008366F2){ref-type="fig"}B). Multivariate Cox regression analysis using the variables that were p\<0.05 in univariate analysis showed that the expression of MUC5B was independently associated with better OS and RFS (p\<0.05; [table 4](#BMJOPEN2015008366TB4){ref-type="table"}). In a cohort of patients whose resected NSCLC tumours had wild-type *EGFR*, univariate analysis showed significant differences (p\<0.05) in OS in smoking status, stage, venous invasion and adjuvant chemotherapy, and in RFS, lymphatic invasion and venous invasion (see online [supplementary table](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2015-008366/-/DC1) S2). There was no significant difference between the MUC5B-positive patients and MUC5B-negative patients in OS and RFS (5-year OS; 59.5% vs 63.6%, 5-year RFS; 36% vs 48.5%, respectively, [figure 2](#BMJOPEN2015008366F2){ref-type="fig"}C, D). Expression of MUC5AC in NSCLC was not associated with OS and RFS regardless of *EGFR* mutation status ([figure 3](#BMJOPEN2015008366F3){ref-type="fig"}). These results indicate that MUC5B is a favourable prognostic marker for postoperative patients whose resected NSCLC tumours carry *EGFR* mutation but not for those with wild type-*EGFR*.

###### 

Univariate analysis for OS and RFS in EGFR-mutant patients with NSCLC

  Parameters                  N    OS     RFS             
  --------------------------- ---- ------ -------- ------ --------
  Age (years)                                             
   \<70                       39   75.5            63.6   
   ≥70                        39   76.3   0.7311   41.5   0.1207
  Gender                                                  
   Male                       35   69              54.4   
   Female                     43   81.5   0.3166   51.8   0.813
  Smoking status                                          
   Non-smoker                 43   75.9            49.1   
   Smoker                     36   73.3   0.9754   55.8   0.8508
  MUC5B expression                                        
   Positive                   27   95.8            69.9   
   Negative                   51   65.1   0.0098   44     0.0187
  Tumour size                                             
   \<20 mm                    25   95              85.7   
   ≥20 mm                     44   64.4   0.0058   31.2   0.0001
  Histological type                                       
   Adenocarcinoma             69   78.8            54     
   Squamous cell carcinoma    8    46.9   0.0245   50     0.6369
  Degree of differentiation                               
   Well                       35   90              72.6   
   Moderately                 28   62.3            34.5   
   Poorly                     11   50.6   0.0172   38.1   0.0137
  Stage                                                   
   I                          45   87.8            62.8   
   II/III                     33   59.3   0.0095   38.8   0.0308
  Lymphatic invasion                                      
   Negative                   35   92.3            74.2   
   Positive                   42   62.7   0.0075   35.8   0.0011
  Venous invasion                                         
   Negative                   45   89              66.5   
   Positive                   32   55.7   0.0045   25.9   0.0021
  Adjuvant chemotherapy                                   
   Yes                        33   62              37.5   
   No                         45   82.8   0.2569   63.4   0.0183

Data are p values by Kaplan-Meier analysis.

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; OS, overall survival; RFS, relapse-free survival.

###### 

Multivariate analysis for OS and RFS in EGFR-mutant patients with NSCLC

                                                    HR       95% CI              p Value
  ------------------------------------------------- -------- ------------------- ---------
  OS                                                                             
   MUC5B (positive vs negative)                     0.053    0.0064 to 0.4402    0.0065
   Differentiation (well vs moderately vs poorly)   0.3762   0.1357 to 1.0428    0.0602
   Stage I vs stage II/III                          0.5199   0.1687 to 1.6019    0.2545
   Lymphatic invasion (positive vs negative)        2.9524   0.6572 to 13.2631   0.1578
  RFS                                                                            
   MUC5B (positive vs negative)                     0.2913   0.1233 to 0.6886    0.005
   Stage I vs stage II/III                          0.5937   0.2735 to 1.2888    0.1874
   Lymphatic invasion (positive vs negative)        3.7624   1.5294 to 9.2556    0.0039

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; OS, overall survival; RFS, relapse-free survival.

![Survival curves for patients based on the expression of MUC5B in epidermal growth factor receptor (*EGFR*) mutant or wild-type non-small cell lung cancer (NSCLC). Overall and relapse-free survivals (OS and RFS) for patients with NSCLC carrying *EGFR* mutations or *EGFR* wild type. OS (A) RFS (B) in the patients with *EGF-* mutant type NSCLC and OS (C) and RFS (D) in the patients with EGFR wild-type NSCLC.](bmjopen2015008366f02){#BMJOPEN2015008366F2}

![Survival curves for patients based on the expression of MUC5AC in epidermal growth factor receptor (***EGFR***) mutant or wild type non-small cell lung cancer (NSCLC). Overall and relapse-free survivals (OS and RFS) for patients with NSCLC carrying *EGFR* mutations or *EGFR* wild type. OS (A) RFS (B) in the patients with *EGFR*-mutant type NSCLC and OS (C) and RFS (D) in the patients with *EGFR* wild-type NSCLC.](bmjopen2015008366f03){#BMJOPEN2015008366F3}

Discussion {#s4}
==========

In the present study, we demonstrate that expression of MUC5B in primary *EGFR* mutant NSCLC is associated with longer survival in patients with NSCLC. MUC5B, but not MUC5AC, is a favourable prognostic biomarker for NSCLC in humans carrying *EGFR* mutations. Our study also indicates that adjuvant chemotherapy is not effective for EGFR-mutant patients, suggesting that mutant EGFR-targeting drugs, including gefitinib or erlotinib, should be used as an adjuvant therapy mainly for MUC5B-negative EGFR-mutant patients who have a poorer prognosis than MUC5B-positive EGFR-mutant patients. Our results using MUC5B as a prognosis biomarker for EGFR-mutant patients should be integrated into the ALCHEMIST lung cancer trials to determine patients who would benefit most from the adjuvant therapy.

MUC5B has been assessed as a prognostic biomarker for multiple cancers in several studies, using reverse transcription-PCR, microarray analysis and IHC (see online [supplementary table](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2015-008366/-/DC1) S3).[@R9] Messenger RNA (mRNA) data assessing MUC5B as a prognostic biomarker is available at PrognoScan, a database for meta-analysis of the prognostic value of genes using microarray data deposited to the public domain.[@R15] The prognostic impact of MUC5B expression differed among cancer types. In lung cancer, six microarray studies analysed by PrognoScan did not indicate MUC5B as either a good or a poor prognostic biomarker.[@R16] Immunohistochemical analysis indicated MUC5B as a poor prognosis biomarker (see online [supplementary table](http://bmjopen.bmj.com/lookup/suppl/doi:10.1136/bmjopen-2015-008366/-/DC1) S3), [@R9] [@R14] a finding contradicting our present study. Previous mRNA microarray and immunostaining were based on all NSCLCs independent of driver mutation-based classification, which differs from our analysis, which was based on classification by *EGFR* mutations. The utility of MUC5B as a prognostic factor differed in the two breast cancer studies, depending on the molecular basis of the tumours. In all breast cancers, PrognoScan indicated that MUC5B was associated with poor prognosis;[@R22] [@R23] however, in (estrogen receptor-) positive breast cancers, MUC5B was associated with favourable prognosis,[@R24] indicating the potential importance of tumour classification on a molecular basis. In the present study, we assessed MUC5B as a biomarker for NSCLC based on *EGFR* mutation status rather than on all NSCLCs, identifying MUC5B as a favourable prognosis biomarker for *EGFR* mutant NSCLC.

Regulation of *MUC5B* in *EGFR* mutant NSCLC is not well understood. *MUC5AC* and *MUC5B* genes are closely located at a locus on human chromosome 11. Both are evolutionally conserved gel-forming mucins secreted from airway epithelial cells in the lung. In normal lung, MUC5B is constitutively expressed at higher levels than MUC5AC.[@R25] In asthma and other inflammatory lung diseases, MUC5AC is highly induced in airway goblet cells.[@R25] In idiopathic pulmonary fibrosis (IPF), MUC5B but not MUC5AC is highly expressed in the airway goblet cells.[@R26] [@R27] The single-nucleotide polymorphism (SNP) rs35705950 located at the *MUC5B* promoter is associated with induction of *MUC5B* mRNA in IPF;[@R27] however, we detected the SNP rs35705950 in only one of 27 cases in the *EGFR* mutant NSCLC expressing MUC5B (data not shown), indicating that the SNP is not associated with increased MUC5B in *EGFR* mutant NSCLC. Since MUC5B was induced in *EGFR* mutant lung tumours in *Nkx2--1* heterozygous mice (EGFR^L858R^; Nkx2--1^+/−^), *Muc5b* is suppressed by NKX2--1 in *EGFR* mutant NSCLC in mice.[@R6] Regulatory mechanisms controlling the *MUC5B* gene are not understood in *EGFR* mutant NSCLC in humans. The function of MUC5B in cancer has been analysed using a truncated MUC5B in MCF7 breast cancer cells, truncated MUC5B promoting tumourigenesis of MCF7 cells.[@R13] However, the use of truncated MUC5B may obscure the intrinsic role of full-length MUC5B since there is a possibility that the truncated MUC5B may function in a dominant-negative fashion. In lung, MUC5B is required for mucociliary clearance and innate immunity against bacterial infection.[@R28] The potential functions of MUC5B in lung cancer, including *EGFR* mutant lung cancer, are not known. The present study suggests that MUC5B or processes regulating *MUC5B* may influence the growth and metastasis of *EGFR* mutant NSCLC. MUC5B may serve as a surrogate biomarker influenced by a pathway involved in metastasis and recurrence associated with *EGFR* mutant NSCLC.

In conclusion, our data revealed the clinicopathological significance of MUC5B as a favourable prognostic factor in resected *EGFR* mutant NSCLC. Further studies are necessary to elucidate the gene regulatory mechanism and the function of MUC5B in *EGFR* mutant NSCLC.
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